Table 4 CMC count in advanced melanoma patients with CellSearch and Parsortix.

From: A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells

Patient ID

Sample ID

Time Point

CellSearch count

Parsortix Captured Cells

Parsortix Capture Rate (%)

Parsortix Harvested Cells

1

ps01

T0

1

8

800

3

2

ps02

T0

0

0

100

0

3

ps03

T0

1

16

1600

ND

ps04

P

942

> 3000

> 300

1019

  1. Column 1: Patient ID; column 2: sample ID; column 3: time point; column 4: number of cells captured by CellSearch in 7.5 ml of blood; column 5: number of cells captured by Parsortix system normalized in 7.5 ml of blood; column 6: percentage of Parsortix vs. CellSearch captured cells; column 7: number of cells harvested with Parsortix. Sample ps01 and ps02 were collected from a stage III and IV cutaneous melanoma patient, respectively. Samples ps03 and ps04 were collected from a stage IV uveal melanoma patient at the baseline (T0) and progression (P), respectively. T0 baseline, before starting the therapy, P progression, ND not done.
Back to article page